NextPoint Therapeutics
Latest round
- Series B
Last raised
- Dec 2022
Total raised
- $80M
Investors
- 8
About NextPoint Therapeutics
, operates as a biotechnology research company that offers various therapeutic solutions. The company offers immunotherapy solutions that include novel therapeutic strategies used for the treatment of cancer. The company delivers a new class of monotherapies by providing an approach that integrates foundational science with a defined clinical biomarker and HHLA2 expression. Its approach reactivates immune cells in tumors that are suppressed by HHLA2-driven immune evasion.
Who invested in NextPoint Therapeutics
8 investors across 1 round
See all investors in NextPoint Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Dec 13, 2022
Amount
$80M
Investors
Questions about NextPoint Therapeutics
Who invested in NextPoint Therapeutics?
NextPoint Therapeutics has 8 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NextPoint Therapeutics raised?
NextPoint Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did NextPoint Therapeutics last raise money?
NextPoint Therapeutics's most recent round on record is a Series B, in Dec 2022.
What does NextPoint Therapeutics do?
, operates as a biotechnology research company that offers various therapeutic solutions.
Where is NextPoint Therapeutics headquartered?
NextPoint Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like NextPoint Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at NextPoint Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like NextPoint Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.